| Year |
Citation |
Score |
| 2020 |
Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, et al. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000522. PMID 32804590 DOI: 10.1200/Jco.20.00522 |
0.346 |
|
| 2020 |
Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 32511981 DOI: 10.1016/S1470-2045(20)30168-6 |
0.331 |
|
| 2020 |
Francis JH, Diamond EL, Chi P, Jaben K, Hyman DM, Abramson DH. MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocular Oncology and Pathology. 6: 159-163. PMID 32509759 DOI: 10.1159/000501155 |
0.302 |
|
| 2020 |
Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, et al. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. Jama Oncology. PMID 31971541 DOI: 10.1001/Jamaoncol.2019.6152 |
0.314 |
|
| 2020 |
George S, Heinrich MC, Zalcberg JR, Bauer S, Gelderblom H, Schoffski P, Serrano C, Jones RL, Attia S, D'Amato GZ, Chi P, Reichardt P, Lacouture ME, Cha E, Meade JN, et al. Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Journal of Clinical Oncology. 38: 11539-11539. DOI: 10.1200/Jco.2020.38.15_Suppl.11539 |
0.324 |
|
| 2020 |
Heinrich MC, George S, Zalcberg JR, Bauer S, Gelderblom H, Schoffski P, Serrano C, Jones RL, Attia S, D'Amato GZ, Chi P, Reichardt P, Becker CC, Meade JN, Ruiz-Soto R, et al. Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Journal of Clinical Oncology. 38: 11535-11535. DOI: 10.1200/Jco.2020.38.15_Suppl.11535 |
0.322 |
|
| 2019 |
Antonescu CR, Dickson BC, Swanson D, Zhang L, Sung YS, Kao YC, Chang WC, Ran L, Pappo A, Bahrami A, Chi P, Fletcher CD. Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. The American Journal of Surgical Pathology. PMID 31219820 DOI: 10.1097/Pas.0000000000001297 |
0.332 |
|
| 2019 |
Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, ... Chi P, et al. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. The Oncologist. PMID 31213500 DOI: 10.1634/Theoncologist.2019-0418 |
0.376 |
|
| 2019 |
Kelly CM, Chi P, Dickson MA, Gounder MM, Keohan ML, Qin L, Adamson T, Condy MM, Biniakewitz M, Phelan H, Singer S, Crago AM, Yoon SS, Ariyan CE, Hwang S, et al. A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Journal of Clinical Oncology. 37: 11049-11049. DOI: 10.1200/Jco.2019.37.15_Suppl.11049 |
0.366 |
|
| 2019 |
Rosenbaum E, Jonsson P, Seier K, Chi P, Dickson MA, Gounder MM, Kelly CM, Keohan ML, Qin L, Hensley ML, D'Angelo SP, Tap WD. DNA damage response pathway alterations and clinical outcome in leiomyosarcoma. Journal of Clinical Oncology. 37: 11048-11048. DOI: 10.1200/Jco.2019.37.15_Suppl.11048 |
0.338 |
|
| 2019 |
D'Angelo SP, Conley AP, Kelly CM, Dickson MA, Gounder MM, Chi P, Keohan ML, Livingston JA, Patel S, Adamson T, Kiesler H, Biniakewitz M, Phelan H, Condy MM, Agaram NP, et al. Pilot study of NKTR214 and nivolumab in patients with sarcomas. Journal of Clinical Oncology. 37: 11010-11010. DOI: 10.1200/Jco.2019.37.15_Suppl.11010 |
0.347 |
|
| 2019 |
Dickson MA, Koff A, D'Angelo SP, Gounder MM, Keohan ML, Kelly CM, Chi P, Antonescu CR, Landa J, Qin L, Crago AM, Singer S, Tap WD. Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. Journal of Clinical Oncology. 37: 11004-11004. DOI: 10.1200/Jco.2019.37.15_Suppl.11004 |
0.373 |
|
| 2019 |
Janku F, Heinrich M, Chi P, Razak AA, Mehren Mv, Gordon M, Ganjoo K, Trent J, Jones RL, Gelderblom H, Running K, Wang J, Ruiz-Soto R, George S. Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct058 |
0.321 |
|
| 2019 |
Mehren Mv, Serrano C, Bauer S, Gelderblom H, George S, Heinrich M, Schöffski P, Zalcberg J, Chi P, Jones RL, Reichardt P, Attia S, D’Amato G, Meade J, Shi K, et al. INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.087 |
0.307 |
|
| 2018 |
George S, Heinrich M, Chi P, Razak A, von Mehren M, Gordon M, Ganjoo KN, Somaiah N, Trent JC, Rodon Ahnert J, Wolf J, Ruiz-Soto R, Rosen O, Janku F. Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii576-viii577. PMID 32137524 DOI: 10.1093/Annonc/Mdy299.002 |
0.34 |
|
| 2018 |
Chang JC, Zhang L, Drilon AE, Chi P, Alaggio R, Borsu L, Benayed R, Travis WD, Ladanyi M, Antonescu CR. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK gene rearrangements. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30550870 DOI: 10.1016/J.Jtho.2018.12.003 |
0.313 |
|
| 2018 |
Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, ... Chi P, et al. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs. PMID 30101387 DOI: 10.1007/S10637-018-0648-Z |
0.347 |
|
| 2018 |
Xie Y, Cao Z, Wong EW, Guan Y, Ma W, Zhang JQ, Walczak EG, Murphy D, Ran L, Sirota I, Wang S, Shukla S, Gao D, Knott SR, Chang K, ... ... Chi P, et al. COP1-DET1-ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. The Journal of Clinical Investigation. PMID 29360641 DOI: 10.1172/Jci94840 |
0.325 |
|
| 2018 |
George S, Heinrich MC, Abdul Razak AR, Chi P, Gordon MS, Ganjoo KN, von Mehren M, Somaiah N, Trent JC, Su Y, Ruiz-Soto R, Rosen O, Janku F. Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618. Journal of Clinical Oncology. 36: 11511-11511. DOI: 10.1200/Jco.2018.36.15_Suppl.11511 |
0.331 |
|
| 2018 |
Xie Y, Cao Z, Wong WP, Guan Y, Zhang J, Walczak E, Murphy D, Ran L, Sirota I, Wang S, Shukla S, Gao D, Wongvipat J, Knott S, Chang K, ... ... Chi P, et al. Abstract B13: COP1-ETS axis regulates ERK transcriptional output and modulates sensitivity to MAPK inhibitors Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-B13 |
0.314 |
|
| 2018 |
Ran L, Murphy D, Sher J, Cao Z, Wang S, Walczak E, Guan Y, Xie Y, Shukla S, Zhan Y, Antonescu CR, Chen Y, Chi P. Abstract A15: Modeling sporadic gastrointestinal stromal tumor with BRAFV600E mutation Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-A15 |
0.343 |
|
| 2018 |
Janku F, Heinrich M, Razak A, Gordon M, Chi P, Ganjoo K, Mehren Mv, Somaiah N, Lee J, Kuida K, Soto RR, Rosen O, George S. Abstract CT029: Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct029 |
0.315 |
|
| 2017 |
Ran L, Chen Y, Sher J, Wong WPE, Murphy D, Zhang JQ, Li D, Deniz K, Sirota I, Cao Z, Wang S, Guan Y, Shukla S, Li KY, Chramiec A, ... ... Chi P, et al. FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor (GIST). Cancer Discovery. PMID 29162563 DOI: 10.1158/2159-8290.Cd-17-0468 |
0.33 |
|
| 2017 |
Owosho AA, Estilo CL, Huryn JM, Chi P, Antonescu CR. A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head and Neck Pathology. PMID 28762137 DOI: 10.1007/S12105-017-0841-Y |
0.316 |
|
| 2017 |
Ran L, Murphy D, Sher J, Cao Z, Wang S, Walczak E, Guan Y, Xie Y, Shukla S, Zhan Y, Antonescu CR, Chen Y, Chi P. ETV1-positive cells give rise to BRAFV600E mutant gastrointestinal stromal tumors. Cancer Research. PMID 28539323 DOI: 10.1158/0008-5472.Can-16-3510 |
0.35 |
|
| 2017 |
Kelly CM, Shoushtari AN, Qin L, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Sjoberg A, Mcfadyen C, Hwang S, Heinemann M, Francis J, Singer S, DeMatteo RP, Antonescu CR, ... Chi P, et al. A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 35: 11039-11039. DOI: 10.1200/Jco.2017.35.15_Suppl.11039 |
0.316 |
|
| 2017 |
Kelly CM, Bowler TG, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Vonya T, Yoon SS, Singer S, DeMatteo RP, Antonescu CR, Zehir A, Ladanyi M, Solit DB, Chi P, et al. The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology. 35: 11010-11010. DOI: 10.1200/Jco.2017.35.15_Suppl.11010 |
0.337 |
|
| 2016 |
D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth M, Sjoberg A, Streicher H, Takebe N, et al. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib Plus Ipilimumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28007774 DOI: 10.1158/1078-0432.Ccr-16-2349 |
0.306 |
|
| 2016 |
Shoushtari AN, Landa J, Kuk D, Sanchez A, Lala B, Schmidt N, Okoli C, Chi P, Dickson MA, Gounder MM, Keohan ML, Crago AM, Tap WD, D'Angelo SP. Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma. 2016: 3547497. PMID 27313489 DOI: 10.1155/2016/3547497 |
0.319 |
|
| 2015 |
Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST. The American Journal of Surgical Pathology. PMID 26645727 DOI: 10.1097/Pas.0000000000000564 |
0.304 |
|
| 2015 |
Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH, Landa I, Button J, Lailler N, Sboner A, Gao D, ... ... Chi P, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. PMID 26444240 DOI: 10.1038/Nature15258 |
0.343 |
|
| 2015 |
Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, Rossi F, Wongvipat J, Taguchi T, Tap WD, Mellinghoff IK, ... ... Chi P, et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discovery. 5: 304-15. PMID 25572173 DOI: 10.1158/2159-8290.Cd-14-0985 |
0.364 |
|
| 2015 |
Hechtman JF, DeMatteo R, Nafa K, Chi P, Arcila ME, Dogan S, Oultache A, Chen W, Hameed M. Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. Annals of Surgical Oncology. PMID 25564173 DOI: 10.1245/S10434-014-4332-Z |
0.315 |
|
| 2015 |
Chi P, Qin L, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev B, Crago AM, Yoon SS, Ulaner GA, Martindale M, Condy MM, Phelan H, et al. A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 33: 10507-10507. DOI: 10.1200/Jco.2020.38.15_Suppl.11508 |
0.37 |
|
| 2015 |
Gounder MM, Zer A, Tap WD, Gupta AA, Keohan ML, Dickson MA, D'Angelo SP, Chi P, Tanner LR, Konen T, Rashal T, McCauley D, Saint-Martin J, Carlson R, Marshall T, et al. A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis. Journal of Clinical Oncology. 33: 10569-10569. DOI: 10.1200/Jco.2015.33.15_Suppl.10569 |
0.343 |
|
| 2014 |
Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, Qin LX, Viale A, ... ... Chi P, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics. 46: 1227-32. PMID 25240281 DOI: 10.1038/Ng.3095 |
0.302 |
|
| 2014 |
Shoushtari AN, Qin L, Kuk D, Magnan HD, Modak S, Wolden SL, Cho EJ, Pallos V, Grubman O, Viny AD, Carvajal RD, Chi P, D'Angelo SP, Dickson MA, Keohan ML, et al. Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor (DSRCT). Journal of Clinical Oncology. 32: 10582-10582. DOI: 10.1200/Jco.2014.32.15_Suppl.10582 |
0.31 |
|
| 2014 |
Ran L, Sirota I, Cao Z, Murphy D, Shukla S, Rossi F, Wongvipat J, Tap WD, Besmer P, Antonescu CR, Chen Y, Chi P. Abstract 3396: Dual lineage inhibition of ETV1 and KIT disrupts the ETV1-KIT feed forward circuit and potentiates imatinib antitumor effect in GIST oncogenesis Cancer Research. 74: 3396-3396. DOI: 10.1158/1538-7445.Am2014-3396 |
0.363 |
|
| 2013 |
Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin L, Rathbone DD, Ustoyev Y, Crago AM, Singer S, Schwartz GK, Condy MM. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma. Journal of Clinical Oncology. 31: 10512-10512. DOI: 10.1200/Jco.2013.31.15_Suppl.10512 |
0.312 |
|
| 2010 |
Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467: 849-53. PMID 20927104 DOI: 10.1038/Nature09409 |
0.332 |
|
| 2003 |
Chi P, Greengard P, Ryan TA. Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron. 38: 69-78. PMID 12691665 DOI: 10.1016/S0896-6273(03)00151-X |
0.585 |
|
| 2002 |
Feng J, Chi P, Blanpied TA, Xu Y, Magarinos AM, Ferreira A, Takahashi RH, Kao HT, McEwen BS, Ryan TA, Augustine GJ, Greengard P. Regulation of neurotransmitter release by synapsin III. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 4372-80. PMID 12040043 DOI: 10.1523/Jneurosci.22-11-04372.2002 |
0.617 |
|
| 2002 |
Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. The Journal of Physiology. 540: 761-70. PMID 11986366 DOI: 10.1113/Jphysiol.2001.013376 |
0.664 |
|
| 2001 |
Chi P, Greengard P, Ryan TA. Synapsin dispersion and reclustering during synaptic activity. Nature Neuroscience. 4: 1187-93. PMID 11685225 DOI: 10.1038/Nn756 |
0.585 |
|
| Show low-probability matches. |
